-SOLVE FSHD, a venture philanthropy organization dedicated to accelerating treatments for facioscapulohumeral muscular dystrophy (FSHD), and Modalis Ther...
As the world recalibrates its life sciences infrastructure post-pandemic, Australia is stepping up as a regional powerhouse in biomanufacturing—espec...
Nxera Pharma Co., Ltd. announces that it has achieved a development milestone under its multi-target collaboration and license agreement with Eli Lilly a...
- Agreement grants Astellas exclusive worldwide rights (excluding China's mainland, Hong Kong, Macao and Taiwan region) to develop and commercialize XNW2...
As regulatory uncertainty grows in the United States, US biotechs are increasingly looking to Australia as a stable and predictable launchpad for early-p...
Fujirebio announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the company’s Lumipulse® G pTau 217/&beta...
Microba Life Sciences Limited, a precision microbiome company, announces preliminary results from the analysis of over 4,600 MetaXplore™ GI P...
Biocom California, the association representing the California life science industry, and KoreaBIO, a life science trade association which seeks to solid...
Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit Pharmaceuticals", "Conduit" or the “Company”) today announces that the Korean Intellectu...
600-patient study to assess efficacy of rhu-pGSN, an immune system regulator that interrupts the NLRP3 inflammasome and boosts macrophage clearance of pa...
Complementary nature of these two immunotherapies leads to excellent 17.6-month median Overall Survival in head and neck cancer patients with PD-L1 CPS...
Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) provides an update on operational activities and reports its consolidated resu...
Scorpius Holdings, Inc. (OTC: SCPX), a biomanufacturing company dedicated to advancing therapeutic production capabilities, today announced a comprehensi...
- Recorded Q1’25 consolidated revenue of KRW 1.3 trillion - Recorded Q1’25 consolidated operating profit of KRW 486.7 billion - Company exp...
© 2025 Biopharma Boardroom. All Rights Reserved.
